Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

588.34 -8.51 (-1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
49 50 Next >
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)  
Via Benzinga
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Regeneron Pharmaceuticals Unusual Options Activity For April 25
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 20
Via Benzinga
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at... 
Via Benzinga
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio
With so many rumblings in the equities space, investors may be best served taking on the top blue-chip stocks to buy. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 05
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent Director 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For March 28
Via Benzinga
MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate
Via Benzinga
Investing $1,000 In These 2 Top Stocks Would Be a Great Move
Both have beaten the market over the past year. 
Via The Motley Fool
2 Top Growth Stocks That Could Soar This Spring
Exciting news on the way for both of these companies could send their stock prices screaming higher. 
Via The Motley Fool
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
Benchmark cut the price target for CuriosityStream Inc. (NASDAQ: CURI) from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in... 
Via Benzinga
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc. 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback